a trend toward significanceP = 0.09
When considering the TNBC cohort only, the addition of Paclitaxel and Alisertib significantly reduced progression-free survival, while a trend toward significance was observed in overall survival (P = 0.09).
When considering the TNBC cohort only, the addition of Paclitaxel and Alisertib significantly reduced progression-free survival, while a trend toward significance was observed in overall survival (P = 0.09).